Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifabutin Triple Therapy for H. pylori Rescue
NCT04879992Completed
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- May 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of rifabutin in Helicobacter pylori infection (2 arms), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Helicobacter pylori eradication rate. Started May 2021; status: completed.
02
Drugs
rifabutin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT04879992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04879992.